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Abstract: Introduction: Preeclampsia is an exacerbation of a generalized inflammatory response, 
physiologically present in the third trimester of pregnancy. Aim: The aim of the study consists in 
the evaluation of proinflammatory cytokine TNF-α in the context of preeclampsia. Material and 
Method: A transversal study was performed in three groups of patients: non-pregnant patients, 
patients with normal pregnancies in the third trimester, patients with preeclampsia. Serum TNF-α 
levels were determined using the immunometric sandwich EIA method. Results:  The results 
obtained confirm a significant increase (p<0.01) in circulating TNF-α levels in the last trimester of 
pregnancy, compared to the non-pregnant status. Significantly increased serum TNF-α 
concentrations (p<0.001) were also found in pregnant patients with preeclampsia, compared to 
normotensive pregnant women. Conclusion: This proinflammatory cytokine can be a potential 
marker of the severity of the preeclamptic syndrome, without being an indicator of the fetal status 
at birth. 
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Introduction 
The absence of the rejection of the semiallogenic fetus by the activated maternal immune system 
is a true immunological paradox which is not yet completely understood. 
Preeclampsia as well as recurrent abortion are considered by the majority of obstetricians the 
result of the alteration of immune physiological pregnancy maintaining processes. 
During the course of human pregnancy, there are two immunologically distinct maternal-fetal 
interfaces, which are spatially and even temporally separate. The first interface is situated at decidual 
level and includes the interactions between the immune maternal decidual cell population and the 
invasive extravillous  cytotrophoblast. This interface is dominant in early pregnancy and almost 
disappears in the third trimester, with the regression of invasive trophoblast. The second interface 
includes the interactions between the circulating maternal immune cells and the 
syncytiotrophoblast, which forms the villous surface of the human hemochorial placenta. These 
interactions involve the systemic maternal immune response [1]. 
This interface is activated with the onset of uteroplacental circulation and is enhanced with the 
growth of the placenta, to become dominant in the third trimester of pregnancy. 
At the level of the first interface, a leukocyte infiltration and an increased production of 
proinflammatory cytokines (IL-12, IL-15, IL-18, INF-y) are found, while at systemic level, in 
pregnancy compared to non-pregnant status, leukocytosis and leukocyte activation, endothelial 
complement activation, coagulation and thrombocyte activation are seen, accompanied by an 
increased synthesis of proinflammatory cytokines (IL-12, IL-6, IL-18, IL-8, TNF-α, INF-y). 
In preeclampsia, the presence of a maternal inflammatory response is supported, which is much 
more intensely generalized than in normal pregnancy. 
The main objective of the study consists in the evaluation of proinflammatory cytokine TNF-α 
in the context of preeclampsia [1, 2].  MIHU Dan, COSTIN Nicolae, BLAGA Ligia D., CIUCHINĂ Septimiu, POP Raluca  B. 
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Material and Method 
A transversal study was performed in the following three groups: 
o  Group 1 (preeclampsia - PE) included 40 pregnant women selected according to the following 
inclusion criteria: pregnant patients with preeclampsia (moderate or severe form), third 
trimester of pregnancy, single fetus pregnancy. For the diagnosis of preeclampsia, the 
classification system proposed by U.S. NHBPEP Working Group 2000 and adopted by ACOG 
was used: 
-  blood pressure values > 140/90 mmHg/ on two examinations repeated at an interval 
of minimum 6 hours and maximum 7 days  
-  proteinuria ≥ 30 mg/dl (in two urine samples taken at an interval of at least 4-6 
hours) 
-  arterial hypertension and proteinuria occurred after 20 weeks of amenorrhea in a 
previously normotensive pregnant woman and were normalized within 12 weeks 
postpartum. 
o  Group 2 (normal pregnancy - NP) included 40 pregnant women with normal pregnancies, 
according to the following inclusion criteria: normotensive pregnant women during the entire 
period of pregnancy and postpartum, third trimester of pregnancy, single fetus pregnancy, 
pregnancy evolution and birth within physiological limits. 
o  Group 3 (control group - C) was represented by 30 patients selected according to the following 
inclusion criteria: healthy non-pregnant women during the reproductive period. 
After the obtaining of the informed consent, for each person included in the study, a form 
containing general and anthropometric data, family history and personal history of disease was 
completed. For the pregnant women included in the study, data relating on the current pregnancy 
were additionally recorded. The pregnant women were followed up during the pregnancy and birth 
period and for 12 weeks postpartum. At birth, the type of delivery (vaginal delivery or cesarean 
section), fetal weight and the Apgar score were recorded. Subsequently, the data resulting from the 
clinical and laboratory examination were added to the forms. The results obtained were introduced 
in a Microsoft Office Access data base. 
From each subject included in the study, 10 ml blood were taken by venous puncture and 
collected in test tubes without anticoagulant. The serum obtained by centrifugation was divided into 
triplicates and stored in 600µl freezing tubes at a temperature of -200 C, until testing, in order to 
avoid repeated freezing-defreezing cycles. 
Serum TNF-α levels were determined by the immunometric sandwich EIA technique, using the 
human TNF-α EIA kit 589201, Cayman Chemical Company, USA. The detection limit was 1.5 
pg/ml.  
The results obtained were expressed as representative indices and indicators, which were 
illustrated depending on relevance as figures, tables or diagrams. For numerical variables, dispersion 
and centrality indices were calculated: mean, median, standard deviation, standard error. For the 
comparison of quantitative variables and of the differences between their means, the t Student test 
and the ANOVA test were used. 
For the evaluation of the relationship between two quantitative variables, regression and 
correlation calculations were used. The correlation coefficient (Pearson index, r) for numerical data 
may take values between –1 and 1. For the illustration of the relationship between two or more 
evaluated variables, scatter plots were used, the presence of a linear relationship of the number of 
points being enhanced by the illustration of a regression line. For statistical significance, the 
threshold value p<0.05 was considered. Implication of Tumor Necrosis Factor - Alpha in Preeclampsia 
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Results 
The mean serum TNF-α concentration in the three analyzed groups were: 
o  Group 1 (PE), the mean serum TNF- α concentration was 14.15 pg/ml; variation limits 0-32.67 
(CI 95%; 11.48-16.38); SD ± 8.37. 
o  Group 2 (NP) the mean serum TNF-α concentration was 5.71 pg/ml; variation limits 0-14.8 
(CI 95%; 4.63-6.79); SD ±3.38. 
o  Group 3 (C) the mean serum TNF-α concentration was 2.01 pg/ml; variation limits 0-4.01 (CI 
95%; 1.52-2.49); SD ± 1.29 (Fig. 1). 
 
 
Figure 1. Mean serum TNF-α concentration ± SD for the group preeclampsia (PE), normal 
pregnancy (NP) and control (C); p< 0.001 
 
Statistical calculations: t test and ANOVA test 
o  Group NP versus group C: difference: -3.70 [CI 95%: ( -5) – ( -2.4)], p <0.001. 
o  Group PE versus group NP: difference: - 8.44 [CI 95%: ( - 11.28 ) – ( - 5.6 )], p < 0.01. 
ANOVA test: Highly statistical = 46.35, p < 0.001. 
By following the relationship between the serum TNF-α concentration and the markers of the 
severity of preeclampsia, we obtained the following results: 
o  Regarding the relationship between serum TNF-α concentration and systolic BP values in 
preeclampsia, no significant correlation was obtained. The correlation was positive and highly 
significant between serum TNF-α concentration and diastolic BP (Fig. 2). 
o  For group 1 (PE), a significant positive correlation was found between serum TNF-α and uric 
acid concentrations (Fig. 3).   
o    No significant correlation was found between proteinuria levels and serum TNF-α 
concentration in preeclampsia (Fig. 4).  
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Figure 2. Relationship between serum TNF-α concentration and systolic/diastolic blood pressure 
in preeclampsia 
 
 
Figure 3. Relationship between serum TNF-α concentration and uric acid (PE group) 
 
Figure 4. Relationship between serum TNF-α  concentration and proteinuria (PE group) Implication of Tumor Necrosis Factor - Alpha in Preeclampsia 
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By analyzing the relationship between serum TNF-α concentration and some fetal parameters at 
birth, we obtained the following results:  
  - For group 1 (PE) a negative but statistically insignificant correlation was found both 
between serum TNF-α concentration and fetal weight at birth and between serum TNF-α 
concentration and Apgar score at birth (Fig. 5, 6). 
 
 
Figure 5. Relationship between serum TNF-α concentration and fetal weight at birth (PE group) 
 
Figure 6. Relationship between serum TNF-α concentration and Apgar score (PE group) 
 
Discussion 
According to our results, the last trimester of pregnancy is characterized by a significant increase 
(p<0.01) in circulating TNF-α levels compared to the non-pregnant status. Similar results were 
reported by Anim-Nyame et al., who determined TNF-α concentrations in 18 pregnant patients 
with normal pregnancies compared to the non-pregnant status (59.75 ± 1.59 µg/ l in the third 
trimester of pregnancy versus 34.89 ± 4.0 µg/l in non-pregnant patients; p < 0.0001 ) [3]. MIHU Dan, COSTIN Nicolae, BLAGA Ligia D., CIUCHINĂ Septimiu, POP Raluca  B. 
 
  16
Teran et al. evaluated serum TNF-α concentrations in a group of 26 pregnant women with 
normal pregnancies compared to 21 healthy non-pregnant women and obtained similar results to 
our study (8.31 ± 1.55 pg/ ml in the third trimester of pregnancy versus 2.76 ± 0.41 pg/ml in non-
pregnant women; p < 0.001) [4]. 
A number of longitudinal studies have assessed the influence of pregnancy on circulating TNF-α 
levels. Although an increase in circulating TNF-α levels is generally found during the course of 
pregnancy, this does not reach statistical significance in all the presented studies. The differences 
between the results might be at least partly explained by the different methods as well as by the 
reduced plasma half life of this cytokine [5,6]. 
Following our researches, we detected significantly increased serum TNF-α concentrations 
(p<0.001) in pregnant women with preeclampsia compared to normotensive pregnant women with 
the same gestational age (p=0.07). 
Due to the pleiotropic effects of TNF-α, this cytokine has been intensely studied in 
preeclampsia in connection to various pathophysiological and immunological aspects found in this 
syndrome. Many studies in the literature have evaluated circulating TNF-α levels in preeclampsia as 
a bioactive or immunoreactive agent, with different results depending on the chosen study method. 
The results obtained are extremely controversial, increased, unchanged or even insignificantly 
decreased circulating TNF-α levels being reported in pregnant women with preeclampsia compared 
to normal pregnancy in the last trimester [3,4,7-10]. 
The biological effects of TNF-α are initiated after the binding of the cytokine to one of the two 
high affinity receptors situated at the surface of the target cells: TNF – RI (TNF p 55, CD 120a) 
and TNF – RII (TNF p 75, CD 120 b) [11]. 
It has been demonstrated that during gestation, soluble TNF-α receptors (sTNF-R) have a 
parallel evolution to that of TNF-α. Soluble receptors have a predictive value in the development of 
preeclampsia, increased concentrations of both receptors being detected in the third trimester of 
pregnancy in women subsequently developing preeclampsia [12]. 
Many authors have investigated sTNF-R levels during the last trimester of pregnancy in 
pregnant women with preeclampsia compared to normal pregnant women and reported high 
concentrations of the two receptors in preeclampsia [13,14]. 
There are only a few studies in the literature that have evaluated the predictive value of plasma 
TNF-α concentrations in preeclampsia [15,16]. 
The source of high circulating levels of inflammatory cytokines, including TNF-α, in pregnant 
women with preeclampsia has not yet been identified. TNF-α is located in the placenta in villous 
stromal cells, in the cytotrophoblast and the syncytiotrophoblast, as well as in the invasive 
trophoblast. One of the most studied hypotheses is the excessive production and release of TNF-α 
from the preeclamptic placenta as a consequence of hypoxia [17-19]. 
Another potential source of TNF-α in preeclampsia are activated maternal leukocytes. 
As monocytes/ macrophages are generally the main reservoir of proinflammatory cytokines and 
are the first cells to be activated in non-specific immune responses, these can be good candidates 
for excessive TNF-α synthesis in preeclampsia [20,21]. 
Activated neutrophils are another TNF-α source in normal and pathological pregnancy [22]. 
Decidual macrophages and neutrophils can also be the source of this proinflammatory cytokine, 
these cells being activated and in higher numbers in preeclampsia [23]. 
In our study, maternal serum TNF-α concentration seems to be a marker of the severity of the 
preeclamptic syndrome, being positively and significantly correlated with both diastolic BP values 
and serum uric acid concentration. 
Gonzalez et al. also reported highly significant positive correlations between serum TNF-α 
concentration and systolic/ diastolic BP values, as well as between TNF-RI and TNF-RII 
concentrations and BP values [13]. 
TNF-α does not seem to be an indicator of fetal status at birth; in our study there is no 
significant correlation between cytokine concentrations and fetal weight, Apgar score, respectively, 
at birth in preeclampsia. 
Unlike our results, Radaelli et al. reported a negative correlation between maternal TNF-α levels 
at birth and fetal weight at birth (r = -0.47; p< 0.05; n = 18) [24]. Implication of Tumor Necrosis Factor - Alpha in Preeclampsia 
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In vitro studies suggest the fact that TNF-α may limit the migration of trophoblast cells in 
maternal tissues and may inhibit trophoblast DNA synthesis [25]. 
It has also been noted that excessive cytokine release in preeclampsia may restrict the invasion 
of endovascular cytotrophoblast at the level of spiral arteries [26]. 
Physiological TNF-α synthesis plays a protective role, but the overexpression of the cytokine as 
the result of genetic or environmental stimuli induces direct structural and functional changes in 
endothelial cells [27]. 
Conclusions 
1.  Serum immunoreactive TNF-α concentrations were significantly increased in the last trimester 
of gestation in preeclamptic women compared to normotensive pregnant women and the 
control group.  
2.  The positive and significant correlation of TNF-α with diastolic BP and uric acid levels makes 
this cytokine a potential marker of the severity of the preeclamptic syndrome. 
3.  TNF-α is not an indicator of fetal status at birth in preeclampsia. 
4.  Preeclampsia is an exacerbation of a generalized inflammatory response, physiologically present 
in the last trimester of pregnancy.  
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